Edwards Lifesciences is trading in a bullish trend and several arguments are in favor of the continuation of this trend.

From a fundamental viewpoint, the medical device company is strong. It reported recently third quarter results that beat Wall Street expectations. The Thomson Reuters consensus revised regularly upward EPS estimates of the company for the current year to USD 7.17.

Technical patterns are in the green: prices are up for several months. A bullish gap has recently arisen. The movement should continue in the coming trading sessions. Indeed, the 20-day moving average upward oriented should help to reach new highest levels toward the USD 133.

In consequence, investors can take a long position in Edwards Lifesciences with a first target at USD 132.90. However, a stop loss will be set under the recent gap at USD 114.9.